Summit Therapeutics Inc 8-K, filed Dec 21, 2022
Summit Therapeutics Inc. (SMMT)
8-K
2022-12-21
For: 2022-12-21
View Original
Added on
April 09, 2026
About this 8-K
Summit Therapeutics Inc filed this 8-K on December 21, 2022.
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): December 21, 2022
| (Exact Name of Registrant as Specified in Its Charter) | ||||||||
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||
Registrant’s Telephone Number, Including Area Code: 617 -514-7149
| Not applicable | ||
| (Former Name or Former Address, If Changed Since Last Report) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01 | Other Events. | ||||
On December 21, 2022 Summit Therapeutics Inc. (the “Company”) filed an amendment on Form 10-K/A to the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 to correct the date on the predecessor auditor opinion for the year ended December 31, 2020, from March 17, 2022 to March 31, 2021, and to correct the tenure statement on such report from 2020 to 2021.
Except for these corrections, no other changes have been made to the Company's Annual Report on Form 10-K for the fiscal year ending December 31, 2021.
| Item 9.01 | Financial Statements and Exhibits. | ||||
(d) Exhibits
Exhibit Number | Description | ||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| SUMMIT THERAPEUTICS INC. | ||||||||
| Date: December 21, 2022 | By: | /s/ Ankur Dhingra | ||||||
| Chief Financial Officer | ||||||||
| (Principal Financial Officer) | ||||||||